The votes in favor of Merck’s shot are a sigh of relief after Kennedy gutted the panel and tapped replacements, some of whom ...

Merck & Co. Inc. closed 40.46% short of its 52-week high of $134.63, which the company reached on June 25th.

RFK Jr.’s vaccine panel endorsed Merck’s RSV shot for babies, easing fears that his stance might delay rollout.

Iya Khalil, PhD, discusses Merck & Co.’s approach to artificial intelligence (AI), and success in applying the technology, ...

U.S. Health Secretary Robert F. Kennedy Jr.'s newly revamped vaccine advisory panel voted on Thursday to recommend use of ...

Merck & Co., Inc. (NYSE:MRK) is another biopharmaceutical company on the list of the 10 undervalued blue chip stocks analysts ...

The company has raised its payouts for 14 consecutive years, and its nearly 89% growth over the last 10 years provides a ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best and Cheap Stocks to Buy Now. On June 18, Akash Tewari, an analyst from ...

Merck & Co., Inc. (NYSE:MRK) is one of Best Dividend Stocks to Buy for Dependable Growth. Merck & Co., Inc. (NYSE:MRK) is one ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $65.0 to $100.0 for Merck & Co over the last 3 months. Looking at the ...

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable ...